Methenamine/sodium salicylate
over-the-counter UTI drug
Methenamine/sodium salicylate, sold under the brand name Cystex among others, is a combination drug comprising methenamine and sodium salicylate. Methenamine serves as a urinary antiseptic and antibacterial agent, while sodium salicylate is a nonsteroidal anti-inflammatory drug (NSAID) and analgesic. The combination is used for the treatment and prevention of urinary tract infection (UTI) symptoms.
Medical uses
Methenamine, whether used alone or in combination with sodium salicylate, is considered an alternative to antibiotics for the treatment and prevention of UTIs and related symptoms. Unlike antibiotics, methenamine does not contribute to the risk of bacterial resistance.
Available forms
The drug is available over-the-counter (OTC), including in the United States, and is typically taken by mouth three times per day.
Methenamine/sodium salicylate is marketed under several brand names, including Cystex Urinary Pain Relief, AZO Urinary Tract Defense, Uro-Pain Dual Action, and CVS Antibacterial Plus Urinary Pain Relief. Some formulations also include phenazopyridine and are marketed as products like the All-In-One UTI Emergency Kit.
Comparison with methenamine
Methenamine is also available as a prescription drug and is used alone to prevent recurrent UTIs. Clinical evidence supports its efficacy for this indication.
Begin with the source’s own compact description: “Methenamine/sodium salicylate” is over-the-counter UTI drug. The dossier treats that line as a proposition to test through Methenamine, sodium and salicylate, not as a finished interpretation.
Why this record matters
The phrase “over-the-counter UTI drug” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Dec 21, 2025. The linked authority identifier is Q130741884. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Methenamine/sodium salicylate”, its source revision and the description used here.
- Expand the search: follow Methenamine/sodium salicylate primary sources, Methenamine/sodium salicylate archive and Methenamine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Methenamine/sodium salicylate”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Methenamine/sodium salicylate” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.